Natalia Neparidze, MD, Yale School of Medicine, New Haven, CT, discusses the findings of a Phase Ib/II study (NCT05002816) investigating the safety and tolerability of combination therapy with elotuzumab and belantamab mafodotin in patients with relapsed refractory (R/R) multiple myeloma (MM). This combination had a manageable safety profile with no dose-limiting toxicities (DLTs) reported and demonstrated encouraging preliminary efficacy in a heavily pretreated cohort of patients. This interview took place during the 2024 American Society of Clinical Oncology (ASCO) Meeting in Chicago, IL.
These works are owned by Magdalen Medical Publishing (MMP) and are protected by copyright laws and treaties around the world. All rights are reserved.